Skip to main content

Table 1 Baseline demographics and sample characteristics of cognitively intact DIAD mutation carriers and non-carriers

From: Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer’s disease

  DIAD mutation non-carriers (n = 102) DIAD mutation carriers (n = 119) p value
Age, years, mean (SD) 38.99 (10.75) 36.45 (9.24) 0.060
Male, n (%) 44 (43.13) 58 (48.73) 0.405
Education, years, mean (SD) 15.15 (2.88) 14.92 (3.05) 0.566
APOE carrier status    0.600
APOE ε2/ε2, ε2/ε3, ε3/ε3 carriers, n (%) 72 (70.06) 83 (69.7)  
APOE ε2/ε4 carriers, n (%) 6 (5.88) 4 (3.36)  
APOE ε3/ε4, ε4/ε4 carriers, n (%) 24 (23.52) 32 (26.89)  
Parental age of onset, years, mean (SD) 46.85 (6.37) 48.32 (7.25) 0.179
EYO, years, mean (SD) −9.40 (11.92) −11.51 (9.40) 0.078
DIAD mutation type    0.863
APP, n (%) 20 (19.60) 20 (16.80)  
PS1, n (%) 69 (67.65) 83 (69.75)  
PS2, n (%) 13 (12.75) 16 (13.45)  
MMSE, mean, (SD) 29.39 (0.83) 29.08 (1.19) 0.052
CSF Aβ1–42, mean, pg/ml (SD)^ 461.14 (138.27) 363.66 (166.72) < 0.001
CSF p-tau181, mean, pg/ml (SD) 29.64 (11.96) 53.44 (30.65) < 0.001
CSF t-tau, mean, pg/ml (SD) 54.86 (25.47) 92.06 (62.16) < 0.001
  1. P values were assessed using family-level random-effects models for the continuous variables and categorical variables, taking into account the analysis of multiple family members within the families. CSF cerebrospinal fluid, EYO estimated years to symptom onset, MMSE mini-mental state examination
  2. ^ CSF Aβ1–42 data for the baseline visit were not available for 19 mutation carriers and 23 non-carriers
  3. CSF p-tau181 & CSF t-tau data for the baseline visit were not available for 18 mutation carriers and 21 non-carriers